Trials / Conditions / Stage IV Bladder Cancer AJCC v8

Stage IV Bladder Cancer AJCC v8

21 registered clinical trials studyying Stage IV Bladder Cancer AJCC v8 — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bl NCT06764095	Mayo Clinic	Phase 4
Recruiting	Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metasta NCT06630416	Northwestern University	Phase 2
Recruiting	An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Loc NCT06414317	Roswell Park Cancer Institute	N/A
Recruiting	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Va NCT05756569	Emory University	Phase 2
Terminated	Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer NCT04936230	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo NCT04963153	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in NCT05092958	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastat NCT04579224	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma NCT04848519	Emory University	Phase 2
Terminated	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Suspended	Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Gen NCT03375307	National Cancer Institute (NCI)	Phase 2
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Active Not Recruiting	Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelia NCT03854474	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small NCT03582475	Jonsson Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Loca NCT03601455	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta NCT03237780	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208	National Cancer Institute (NCI)	Phase 1